Flexible pricing could work in Europe
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline recently published its corporate responsibility report, which shone a spotlight on a pricing system that promotes access to affordable medicines, whilst ensuring a healthy return for reinvestment in R&D. The flexible pricing mechanism has been employed successfully by the company to increase access to medicines in middle income countries (MICs), such as Brazil, China, Thailand, India and Indonesia. The question many are asking is whether such a system could be brought to Europe and if so, would it be valuable?
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.